Previous 10 | Next 10 |
Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3 PR Newswire - Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif. , Oct. 24, 2022 /PRN...
Eiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference PR Newswire PALO ALTO, Calif. , Oct. 11, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceut...
Eiger BioPharmaceuticals, Inc. ( NASDAQ: EIGR ), a biotech focused on rare and ultra-rare diseases, slipped ~20% pre-market Wednesday after announcing it would not seek an emergency use authorization (EUA) application in the U.S. for COVID-19 therapy peginterferon lambda. ...
Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback PR Newswire PALO ALTO, Calif. , Oct. 5, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biophar...
Eiger BioPharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference PR Newswire PALO ALTO, Calif. , Sept. 22, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on ...
The shares of commercial-stage biotech Eiger BioPharmaceuticals, Inc. ( NASDAQ: EIGR ) fell ~21% in the pre-market Tuesday after the company announced that the FDA is uncertain about the regulatory path for COVID-19 therapy peginterferon lambda. The update comes after ...
Eiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application PR Newswire PALO ALTO, Calif. , Sept. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-st...
Eiger BioPharmaceuticals to Participate in Three Upcoming Investor Conferences PR Newswire PALO ALTO, Calif. , Sept. 1, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the dev...
On May 18, I wrote the first of three articles stating that healthcare stocks, and specifically biopharmaceuticals, had likely bottomed. XBI was at 68 and IBB 114. Both XBI and IBB have increased since then. I viewed the valuations a few months ago as being compelling in several insta...
Eiger BioPharmaceuticals, Inc. (EIGR) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sarah Mathieson - SVP, Corporate Affairs David Cory - President & CEO Ingrid Choong - SVP-Clinical Development Eldon Mayer - Chief Commer...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...